Advertisement

Topics

Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

08:00 EST 9 Nov 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
− Givosiran Demonstrated Sustained Clinical Activity, with an Over 90 Percent Decrease in Mean Annualized Porphyria Attack Rate, Relative to Baseline – − Safety Profile Encouraging with up to 25 Months of Treatmen...

Other Sources for this Article

Alnylam Pharmaceuticals, Inc.
(Investors and Media)
Christine Regan Lindenboom, 617-682-4340
or
(Investors)
Josh Brodsky, 617-551-8276

NEXT ARTICLE

More From BioPortfolio on "Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...